CLIMB BIO INC (CLYM) Stock Price, Forecast & Analysis
NASDAQ:CLYM • US28658R1068
CLYM Key Statistics, Chart & Performance
The current stock price of CLYM is 7.15 USD. In the past month the price increased by 49.58%. In the past year, price increased by 393.1%.
CLYM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CLYM. When comparing the yearly performance of all stocks, CLYM is one of the better performing stocks in the market, outperforming 99.51% of all stocks.
CLYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLYM. CLYM has a great financial health rating, but its profitability evaluates not so good.
CLYM Financial Highlights
Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 64.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.84% | ||
| ROE | -28.67% | ||
| Debt/Equity | 0 |
CLYM Forecast & Estimates
13 analysts have analysed CLYM and the average price target is 11.66 USD. This implies a price increase of 63.04% is expected in the next year compared to the current price of 7.15.
CLYM Ownership
CLYM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 410.174B | ||
| AMGN | AMGEN INC | 17.23 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.61 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.698B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLYM
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Company Info
CLIMB BIO INC
20 William Street, Suite 145
Wellesley Hills MASSACHUSETTS US
Employees: 17
Phone: 18668572596
CLIMB BIO INC / CLYM FAQ
What does CLYM do?
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Can you provide the latest stock price for CLIMB BIO INC?
The current stock price of CLYM is 7.15 USD. The price decreased by -3.12% in the last trading session.
Does CLIMB BIO INC pay dividends?
CLYM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLYM stock?
CLYM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CLIMB BIO INC (CLYM) stock traded?
CLYM stock is listed on the Nasdaq exchange.